Medical Cannabis Education Has Not Kept Pace With Clinical Reality
Medical cannabis provider knowledge may be far weaker than many clinicians believe. A survey of 879 U.S. healthcare professionals found large gaps between self-rated confidence and objective cannabis knowledge. The findings raise important questions…
The DEA’s New Cannabis Registration System May Matter More Than Legalization Headlines
The DEA’s new cannabis registration system may quietly reshape American cannabinoid medicine. This policy shift could influence research, taxation, institutional acceptance, and physician participation far beyond the headlines. Here is what clinicians…
Justice Department, DEA ordered to reclassify state-licensed medical cannabis as less … – Maui Now
The DEA's ordered reclassification of medical cannabis represents a historic shift that could enhance research opportunities and patient access while maintaining clinical oversight. This federal cannabis reclassification clinical impact extends beyond…
Reclassifying marijuana as a less dangerous drug might only be the first step for Trump
Federal cannabis reclassification to Schedule III represents a landmark shift in medical cannabis policy with significant clinical implications. This regulatory change acknowledges cannabis's therapeutic potential while creating new pathways for research…
OBN officials celebrate reclassification of medical marijuana – KTUL
The DEA's proposed reclassification of marijuana to Schedule III creates significant federal marijuana reclassification medical implications for patients and providers. This regulatory shift acknowledges cannabis medical utility while maintaining…
Research study on Maltese cannabis users (Still open for participants) : r/malta – Reddit
Research on maltese cannabis users research study provides crucial epidemiological data following Malta's recent legalization. This clinical analysis examines the value of Mediterranean cannabis research for evidence-based practice. Understanding usage…
Federal Marijuana Rescheduling Will End Discrimination In Housing, Healthcare And …
Federal cannabis rescheduling patient discrimination policies may soon change as marijuana moves from Schedule I to Schedule III classification. This regulatory shift could eliminate systematic barriers that medical cannabis patients face in housing,…
Federal Marijuana reclassification could reshape medical research and cannabis industry
Federal marijuana rescheduling medical research represents a pivotal moment for cannabis medicine, potentially removing decades-old barriers to rigorous clinical studies. This policy shift could accelerate the development of evidence-based cannabis…
Self-reported reasons for medical and nonmedical cannabis use in Australia: A cross-sectional analysis of the International Cannabis Policy Study 2023.
A 2023 Australian survey found that cannabis users frequently report dual medical-recreational motives rather than distinct categories. This cross-sectional analysis of 3,042 adults reveals that australian medical cannabis use patterns are more nuanced…
What Federal Cannabis Rescheduling Means for Care
Cannabis Schedule III rescheduling marks a major shift in how cannabis is classified and understood at the federal level. This change begins to align policy with clinical reality, affecting research, documentation, and patient access. Cannabis Schedule…